This Bull Market Indicator called NVDA at $116

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

Josep Bassaganya-Riera net worth and biography

Josep Bassaganya-Riera Biography and Net Worth

Major Shareholder of Landos Biopharma

Josep Bassaganya-Riera has served as the Chairman of the Board, President and CEO of Landos Biopharma (NASDAQ: LABP) since Landos’ founding in January 2017. He previously served as the CEO at Biotherapeutics and founded the NIMML Institute. He has published over 200 peer-reviewed articles, book chapters and books on A.I., modeling-driven drug design and computational immunology, and he has contributed 190 patents in immunology, inflammation and autoimmune disease treatment.
He has founded several award-winning Companies, raising over $800 million in non-dilutive and equity financing rounds. Through his entrepreneurial corporate mindset, encapsulated in four pillars: be bold and decisive, never give up, be solution-oriented and do the impossible, Dr. Bassaganya-Riera empowers employees to think outside the box to achieve innovative solutions that promote innovation, excellence, efficiency, and creativity. Dr. Bassaganya-Riera holds a degree in Veterinary Medicine from Universitat Autònoma de Barcelona and a PhD in Nutritional Immunology from Iowa State University.

How old is Josep Bassaganya-Riera?: Dr. Bassaganya-Riera is currently 49 years old. There are 3 older executives and no younger executives at Landos Biopharma. The oldest executive at Landos Biopharma is Dr. Fabio Cataldi M.D., Executive VP & Chief Medical Officer, who is 56 years old. Learn More on Josep Bassaganya-Riera's age.
How do I contact Josep Bassaganya-Riera?: The corporate mailing address for Dr. Bassaganya-Riera and other Landos Biopharma executives is 1800 KRAFT DRIVE SUITE 216, BLACKSBURG VA, 24060. Landos Biopharma can also be reached via phone at 540-218-2232 and via email at [email protected]. Learn More on Josep Bassaganya-Riera's contact information.
Has Josep Bassaganya-Riera been buying or selling shares of Landos Biopharma?: Josep Bassaganya-Riera has not been actively trading shares of Landos Biopharma during the last quarter. Most recently, Josep Bassaganya-Riera sold 3,319 shares of the business's stock in a transaction on Monday, December 20th. The shares were sold at an average price of $47.50, for a transaction totalling $157,652.50. Learn More on Josep Bassaganya-Riera's trading history.

Josep Bassaganya-Riera Insider Trading History at Landos Biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
12/20/2021	Sell	3,319	$47.50	$157,652.50
12/17/2021	Sell	3,600	$48.40	$174,240.00
12/15/2021	Sell	4,300	$50.20	$215,860.00
12/13/2021	Sell	4,000	$53.70	$214,800.00
12/10/2021	Sell	4,000	$57.70	$230,800.00
12/8/2021	Sell	2,553	$66.50	$169,774.50
12/6/2021	Sell	3,600	$61.70	$222,120.00
12/3/2021	Sell	3,600	$61.50	$221,400.00
12/1/2021	Sell	3,223	$70.10	$225,932.30
11/29/2021	Sell	1,543	$75.80	$116,959.40

Josep Bassaganya-Riera Buying and Selling Activity at Landos Biopharma

Landos Biopharma Company Overview

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia.

Today's Range

Now: $22.93

$22.75

$22.94

50 Day Range

MA: $22.54

$21.51

$22.93

2 Week Range

Now: $22.93

$2.50

$22.94

Volume

50,800 shs

Average Volume

19,700 shs

Market Capitalization

$71.77 million

P/E Ratio

N/A

Dividend Yield